SRX Global Inc. 8-K Summary
Business Context and Reporting Period
SRX Global Inc. (NYSE American: SRXH), a Delaware corporation, filed this Current Report on Form 8-K on August 27, 2026. The filing discloses the entry into a Material Definitive Agreement involving a private placement of equity securities.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than periodic financial performance metrics. Key transaction figures include:
- Securities Issued: 3,579 shares of Series C Convertible Preferred Stock.
- Total Purchase Price: $2,862,500.00.
- Payment Method: The purchase price was satisfied by the assignment of Convertible Grid Promissory Notes issued by CERO Therapeutics Holdings, Inc., with an aggregate original principal amount of $2,812,500.00.
- Stated Value: $1,000 per share of Series C Preferred Stock.
- Conversion Price: Fixed at $2.1888 per share of Common Stock, subject to adjustments.
The filing does not provide current revenue, profit, cash flow, or debt levels for SRX Global Inc. outside of the specific transaction details.
Material Changes and Terms
The primary material change is the issuance of the Series C Preferred Stock and the associated rights and restrictions:
- Ranking: Senior to Common Stock and pari passu with Series A and Series B Convertible Preferred Stock.
- Dividends: Payable on an as-if converted basis equal to dividends paid on Common Stock.
- Conversion Rights: Holders may convert at the fixed price or, after stockholder approval, at an alternate price based on the lowest volume-weighted average price (95% or 90% depending on triggering events).
- Redemption: The Company has the right to redeem all shares in cash at 125% of the greater of the conversion amount or the product of the conversion rate and the greatest closing sale price during a specific period.
- Covenants: The Company is restricted from redeeming or repurchasing other capital stock, declaring dividends on other stock, or incurring new indebtedness (except ordinary trade payables) while the Series C is outstanding.
Outlook, Risks, and Contingencies
Stockholder Approval: The Company must seek stockholder approval for the issuance of Common Stock issuable upon conversion of the Series C Shares and exercise of Warrants to comply with NYSE American rules.
Registration Rights: The Company entered into a Registration Rights Agreement requiring the filing of a registration statement with the SEC for the resale of Common Stock issuable upon conversion or warrant exercise.
Triggering Events: Alternate conversion pricing is triggered by events such as suspension of trading, failure to pay dividends, failure to file registration statements, or bankruptcy/insolvency.
Unregistered Sale: The securities were sold in reliance on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the status of the CERO Therapeutics Holdings, Inc. notes assigned as payment to ensure they are valid and enforceable.
- Confirm the timeline and outcome of the required stockholder approval for the issuance of Common Stock upon conversion.
- Review the Certificate of Designations for specific definitions of "Triggering Events" that could alter the conversion price.
- Assess the impact of the restrictive covenants (no new debt, no dividends) on the Company's operational flexibility.
- Monitor the filing of the registration statement required under the Registration Rights Agreement.